The risk of myocarditis in this large cohort study was highest in young males after the second SARS-CoV-2 vaccine dose, and this risk should be balanced against the benefits of protecting against severe COVID-19 disease.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2791253
Archive link: https://web.archive.org/web/20230000000000*/https://jamanetwork.com/journals/jamacardiology/fullarticle/2791253